Description: Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Home Page: www.ipsen.com
65, quai Georges Gorse
Boulogne-Billancourt,
92100
France
Phone:
33 1 58 33 50 00
Officers
| Name | Title |
|---|---|
| Mr. David Loew | MD, CEO & Director |
| Mr. Aymeric Le Chatelier | Executive VP & CFO |
| Dr. Aidan Murphy Ph.D. | Executive VP and Head of Technical Operations |
| Mr. Francois Garnier | Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer |
| Mr. Regis Mulot | Executive VP & Chief Human Resources Officer |
| Ms. Dominique Bery | Head of Nordics & Baltics |
| Mr. Bartosz Bednarz D.D.S. | Executive VP and Head of Global Product & Portfolio Strategy |
| Mr. Philippe Lopes-Fernandes CBO | Executive VP & Chief Business Officer |
| Dr. James Levine M.D., Ph.D. | President of Fondation Ipsen |
| Ms. Mari Scheiffele | Executive VP & President of International |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 10.3093 |
|---|---|
| Trailing PE: | 13.3208 |
| Price-to-Book MRQ: | 2.29 |
| Price-to-Sales TTM: | 2.6632 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5325 |